Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
British Journal of Clinical Pharmacology|March 12, 2011
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human studyZhenhua Xu, Esther Bouman-Thio, Craig Comisar, et al.
Molecular Genetics & Genomic Medicine|October 8, 2020
Whole-exome sequencing identified two novel mutations of DYNC2LI1 in fetal skeletal ciliopathyXinyue Zhang, Yanqin You, Xiaoxiao Xie, et al.
Journal of Clinical Pharmacology|June 9, 2015
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approachYanli Zhuang, Dick E de Vries, Zhenhua Xu, et al.
Journal of Clinical Pharmacology|January 31, 2009
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasisYaowei Zhu, Chuanpu Hu, Ming Lu, et al.
Nature Biotechnology|July 13, 2011
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabJacqueline M Benson, Clifford W Sachs, George Treacy, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 8, 2023
The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodiesMichelle A Pressly, Lambertus A Peletier, Songmao Zheng, et al.
Journal of Clinical Pharmacology|May 2, 2003
Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjectsSuzanne K Swan, Honghui Zhou, Ann Horowitz, et al.
Journal of Clinical Pharmacology|December 12, 2018
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative ColitisYan Xu, Omoniyi J Adedokun, Daphne Chan, et al.
Paediatric Drugs|September 28, 2022
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric PopulationsJocelyn H Leu, Natalie J Shiff, Michael Clark, et al.
Clinical Therapeutics|February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid ArthritisJong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
British Journal of Clinical Pharmacology|March 12, 2011
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human studyZhenhua Xu, Esther Bouman-Thio, Craig Comisar, et al.
Molecular Genetics & Genomic Medicine|October 8, 2020
Whole-exome sequencing identified two novel mutations of DYNC2LI1 in fetal skeletal ciliopathyXinyue Zhang, Yanqin You, Xiaoxiao Xie, et al.
Journal of Clinical Pharmacology|June 9, 2015
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approachYanli Zhuang, Dick E de Vries, Zhenhua Xu, et al.
Journal of Clinical Pharmacology|January 31, 2009
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasisYaowei Zhu, Chuanpu Hu, Ming Lu, et al.
Nature Biotechnology|July 13, 2011
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabJacqueline M Benson, Clifford W Sachs, George Treacy, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 8, 2023
The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodiesMichelle A Pressly, Lambertus A Peletier, Songmao Zheng, et al.
Journal of Clinical Pharmacology|May 2, 2003
Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjectsSuzanne K Swan, Honghui Zhou, Ann Horowitz, et al.
Journal of Clinical Pharmacology|December 12, 2018
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative ColitisYan Xu, Omoniyi J Adedokun, Daphne Chan, et al.
Paediatric Drugs|September 28, 2022
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric PopulationsJocelyn H Leu, Natalie J Shiff, Michael Clark, et al.
Clinical Therapeutics|February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid ArthritisJong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Pageof 15